Antibody data
- Antibody Data
- Antigen structure
- References [2]
- Comments [0]
- Validations
- Flow cytometry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 17-1357-41 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- Anti-CD135 (Flt3) Monoclonal Antibody (BV10A4H2), APC, eBioscience™
- Antibody type
- Monoclonal
- Antigen
- Other
- Description
- Description: The BV10A4H2 monoclonal antibody reacts with human CD135, also known as Flk2/Flt3. A member of the tyrosine kinase receptor family, this 135-150 kDa molecule is expressed by multipotential progenitor cells including primitive B cell and myelomonocytic progenitors in fetal liver and adult bone marrow. Applications Reported: The BV10A4H2 antibody has been reported for use in flow cytometric analysis. Applications Tested: This BV10A4H2 antibody has been pre-titrated and tested by flow cytometric analysis of REH cell line. This can be used at 5 µL (0.5 µg) per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. Excitation: 633-647 nm; Emission: 660 nm; Laser: Red Laser. Filtration: 0.2 µm post-manufacturing filtered.
- Reactivity
- Human
- Host
- Mouse
- Isotype
- IgG
- Antibody clone number
- BV10A4H2
- Vial size
- 25 Tests
- Concentration
- 5 µL/Test
- Storage
- 4° C, store in dark, DO NOT FREEZE!
Submitted references IL1RAP potentiates multiple oncogenic signaling pathways in AML.
NOTCH2 and FLT3 gene mis-splicings are common events in patients with acute myeloid leukemia (AML): new potential targets in AML.
Mitchell K, Barreyro L, Todorova TI, Taylor SJ, Antony-Debré I, Narayanagari SR, Carvajal LA, Leite J, Piperdi Z, Pendurti G, Mantzaris I, Paietta E, Verma A, Gritsman K, Steidl U
The Journal of experimental medicine 2018 Jun 4;215(6):1709-1727
The Journal of experimental medicine 2018 Jun 4;215(6):1709-1727
NOTCH2 and FLT3 gene mis-splicings are common events in patients with acute myeloid leukemia (AML): new potential targets in AML.
Adamia S, Bar-Natan M, Haibe-Kains B, Pilarski PM, Bach C, Pevzner S, Calimeri T, Avet-Loiseau H, Lode L, Verselis S, Fox EA, Galinsky I, Mathews S, Dagogo-Jack I, Wadleigh M, Steensma DP, Motyckova G, Deangelo DJ, Quackenbush J, Tenen DG, Stone RM, Griffin JD
Blood 2014 May 1;123(18):2816-25
Blood 2014 May 1;123(18):2816-25
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Staining of REH cell line with Mouse IgG1 kappa Isotype Control APC (Product # 17-4714-81) (blue histogram) or Anti-Human CD135 (Flt3) APC (purple histogram). Total viable cells were used for analysis.